Gonadotropin-releasing hormone agonists

Gonadotropin-releasing hormone agonists has been studied in 12 papers since 2016: 2 observational studies in people, 1 in animals, 9 reviews; 4 in the past year. The newest paper, Nov 16, 2026: “Hormonal Therapy for Osteoporosis: Mechanisms, Trial Evidence, and Current Place in Fracture Prevention”.

Intervention

12 papers study it10 findingsUpdated

More peptides

2 new papers in 30 daysSee all 12 papers on gonadotropin-releasing hormone agonists

At a glance

The findings reach people, from one lab or study. 3 independent labs in 3 countries.

“with the largest increases observed among those receiving regimens including gonadotropin-releasing hormone agonists.”
Longitudinal trajectories of menopausal symptoms in women receiving endocrine therapy for breast cancer compared with natural menopauseBreast (Edinburgh, Scotland)2026doi:10.1016/j.breast.2026.104947

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 3 countries
  • Funders: Korea National Institute of Health and 5 more
  • Humans2
  • Animals1

What did studies of gonadotropin-releasing hormone agonists find?

4

Studies of gonadotropin-releasing hormone agonists measured 4 outcomes, among them serious adverse events, BMD Z-score and premature ovarian failure.

Serious adverse events

no changein humans1RR 0.99

1 study
  1. Gonadotropin-releasing hormone agonists showed no clear effect on serious adverse events in humans during cyclophosphamide therapy (RR 0.99, 95% CI 0.50-1.93).

    “The incidence of serious adverse events was similar between groups (10 of 36 versus 10 of 34 women; risk ratio: 0.99; 95% CI: 0.50-1.93).”

    Reviewduring cyclophosphamide therapyfemales

    Gonadotropin-releasing hormone agonists during cyclophosphamide for ovarian protection in systemic lupus erythematosus

    Reproduction & fertility

BMD Z-score

downin humans1

1 study
  1. Gonadotropin-releasing hormone agonists decrease BMD Z-score in humans during hormonal suppression.

    “In adolescents, GnRH-agonists predictably reduce BMD Z-scores during hormonal suppression”

    Reviewduring hormonal suppression

    Bone health in gender-diverse individuals: current challenges and future directions

    Hormones (Athens, Greece)

More on BMD Z-score

Premature ovarian failure

no changein humans1

1 study
  1. Gonadotropin-releasing hormone agonists were not clearly linked with premature ovarian failure in humans Following myeloablative hematopoietic cell transplantation.

    “it cannot reduce the incidence of premature ovarian failure in women of reproductive age following myeloablative HSCT.”

    HumansFollowing myeloablative hematopoietic cell transplantationOvary3.75 mg per course; at least 2 coursesfemalesn = 234

    Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation

    Scientific reports

More on Premature ovarian failure

Visible ovarian follicles

no changein humans1

1 study
  1. Gonadotropin-releasing hormone agonists were not clearly linked with visible ovarian follicles in humans (Myeloablative hematopoietic cell transplantation) (16.88% vs. 13.38%, P = 0.474).

    “There was no difference in visible follicles by follow-up ultrasound in the two groups after HSCT (16.88% vs. 13.38%, P = 0.474).”

    HumansMyeloablative hematopoietic cell transplantationOvary3.75 mg per course; at least 2 coursesAfter transplantationfemalesn = 234

    Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation

    Scientific reports

What is gonadotropin-releasing hormone agonists linked with?

6

Studies link gonadotropin-releasing hormone agonists with 6 measures, among them menopausal symptoms, primary ovarian insufficiency and follicle stimulating hormone.

Menopausal symptoms

upin humans1

1 study
  1. Gonadotropin-releasing hormone agonists are associated with menopausal symptoms in humans (Premenopausal women within the breast cancer cohort).

    “with the largest increases observed among those receiving regimens including gonadotropin-releasing hormone agonists.”

    HumansPremenopausal women within the breast cancer cohortregimens including gonadotropin-releasing hormone agonists3 yearsfemales

    Longitudinal trajectories of menopausal symptoms in women receiving endocrine therapy for breast cancer compared with natural menopause

    Breast (Edinburgh, Scotland)

Primary ovarian insufficiency

downin humans1RR 0.16

1 study
  1. Gonadotropin-releasing hormone agonists lower the risk of primary ovarian insufficiency in humans during cyclophosphamide therapy (RR 0.16, 95% CI 0.07-0.37).

    “Premature ovarian insufficiency occurred in 5 of 93 women receiving gonadotropin-releasing hormone agonists and in 28 of 69 controls, corresponding to a risk ratio of 0.16 (95% confidence interval (CI): 0.07-0.37).”

    Reviewduring cyclophosphamide therapyfemalesn = 162

    Gonadotropin-releasing hormone agonists during cyclophosphamide for ovarian protection in systemic lupus erythematosus

    Reproduction & fertility

More on Primary ovarian insufficiency

Follicle stimulating hormone

downin humans1

1 study
  1. Gonadotropin-releasing hormone agonists are associated with follicle stimulating hormone in humans (Myeloablative hematopoietic cell transplantation) (98.00 mIU/ml vs. 117.53 mIU/ml, P = 0.001).

    “The level of FSH at 6-12 months after transplantation was lower (98.00 mIU/ml vs. 117.53 mIU/ml, P = 0.001).”

    HumansMyeloablative hematopoietic cell transplantation3.75 mg per course; at least 2 courses6–12 months after transplantationfemalesn = 234

    Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation

    Scientific reports

More on Follicle stimulating hormone

Menopause-related symptoms

downin humans1

1 study
  1. Gonadotropin-releasing hormone agonists are associated with menopause-related symptoms in humans (Myeloablative hematopoietic cell transplantation) (46.75% vs. 19.75%, P < 0.001).

    “The menopausal symptoms of the patients in the treatment group were reduced after transplantation (46.75% vs. 19.75%, P < 0.001).”

    HumansMyeloablative hematopoietic cell transplantation3.75 mg per course; at least 2 coursesAfter transplantationfemalesn = 234

    Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation

    Scientific reports

More on Menopause-related symptoms

Vaginal bleeding

downin humans1

1 study
  1. Gonadotropin-releasing hormone agonists are associated with vaginal bleeding In the laminar air-flow room during myeloablative hematopoietic cell transplantation (24.68% vs. 79.62%, P < 0.001).

    “The incidence of vaginal bleeding in the LAFR in the treatment group was significantly lower than that in the control group”

    HumansIn the laminar air-flow room during myeloablative hematopoietic cell transplantation3.75 mg per course; at least 2 coursesfemalesn = 234

    Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation

    Scientific reports

More on Vaginal bleeding

Gonadotoxicity

downin humans1

1 study
  1. Gonadotropin-releasing hormone agonists lower the risk of gonadotoxicity in humans (receiving chemotherapy).

    “Ovarian suppression with gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is now recommended as an option to reduce the risk of gonadotoxicity”

    Reviewreceiving chemotherapyovaryduring chemotherapyfemales

    How to Protect Ovarian Function before and during Chemotherapy?

    Journal of clinical medicine

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 14 papers in 12 months

See all 12 papers on gonadotropin-releasing hormone agonists